Yahoo Web Search

Search results

    • Small Business - Salisbury Post | Salisbury Post

      The Salisbury Post· 2 days ago

      At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks

    • Small Business - Picayune Item | Picayune Item

      The Picayune Item· 3 days ago

      Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. PR Newswire RADNOR, Pa., June 4, 2024 RADNOR, Pa., June 4, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP